X4 Pharmaceuticals announces an Investor Day on October 29, 2026, focusing on clinical advancements and mavorixafor for rare hematology diseases.
| Name | X4 Pharmaceuticals, Inc |
|---|---|
| CIK | 0001501697 |
| Tickers | XFOR |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2836 Biological Products, (No Diagnostic Substances) |
| EIN | 273181608 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 857-529-8300 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
X4 Pharmaceuticals announces an Investor Day on October 29, 2026, focusing on clinical advancements and mavorixafor for rare hematology diseases.
Craig Adam R, Executive Chairman of X4 Pharmaceuticals, acquired 4,600 shares, reflecting confidence in the company's future and activity in the biological products sector.
X4 Pharmaceuticals, Inc. has entered a $150 million loan agreement to support its operations and repay existing debts, as detailed in an SEC filing.
821 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001738048-26-000100 | 005-90199 | 261563206 | 34 | 18131 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-005081 | 005-90199 | 261555818 | 34 | 14332 | |||
| 2026-11-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-127412 | 005-90199 | 261554945 | 34 | 19544 | |||
| 2026-11-04 | 10-Q | 10-Q | 0001501697-26-000089 | 001-38295 | 261522121 | 34 | 8494798 | 1 | 1 | |
| 2026-10-29 | 8-K | 8-K | 8.01,9.01 | 0001501697-26-000084 | 001-38295 | 261498137 | 34 | 4479678 | 1 | 1 |
| 2026-10-19 | 4 | FORM 4 | 0001339498-26-000005 | 5243 | ||||||
| 2026-10-08 | 8-K | 8-K | 1.01,1.02,2.03,3.02,7.01,9.01 | 0001501697-26-000081 | 001-38295 | 261450589 | 34 | 175403 | 1 | 1 |
| 2026-10-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-002326 | 005-90199 | 261446103 | 34 | 11601 | |||
| 2026-10-05 | 4 | FORM 4 | 0001501697-26-000078 | 5659 | ||||||
| 2026-10-01 | 144 | xsl144X01/primary_doc.xml | 0001276750-26-000008 | 001-38295 | 261433100 | 33 | 5312 | |||
| 2026-09-21 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001738048-26-000071 | 005-90199 | 261395051 | 34 | 35222 | |||
| 2026-09-09 | 8-K | 8-K | 8.01,9.01 | 0001501697-26-000076 | 001-38295 | 261366019 | 34 | 2844241 | 1 | 1 |
| 2026-09-08 | 8-K | 8-K | 8.01,9.01 | 0001501697-26-000072 | 001-38295 | 261363365 | 34 | 158584 | 1 | 1 |
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-352651 | 005-90199 | 261283770 | 34 | 11495 | |||
| 2026-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-003487 | 005-90199 | 261276439 | 34 | 14317 | |||
| 2026-08-13 | 4 | FORM 4 | 0001501697-26-000070 | 5627 | ||||||
| 2026-08-13 | 4 | FORM 4 | 0001501697-26-000069 | 5660 | ||||||
| 2026-08-13 | 144 | xsl144X01/primary_doc.xml | 0002081729-26-000004 | 001-38295 | 261272973 | 33 | 5290 | |||
| 2026-08-13 | 144 | xsl144X01/primary_doc.xml | 0001339498-26-000003 | 001-38295 | 261272963 | 33 | 5317 | |||
| 2026-08-06 | 10-Q | 10-Q | 0001501697-26-000068 | 001-38295 | 261249010 | 34 | 7057708 | 1 | 1 | |
| 2026-07-30 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002012383-26-003133 | 005-90199 | 261221124 | 34 | 10903 | |||
| 2026-07-01 | 4 | FORM 4 | 0001501697-26-000065 | 5658 | ||||||
| 2026-07-01 | 4 | FORM 4 | 0001501697-26-000064 | 5594 | ||||||
| 2026-07-01 | 3 | FORM 3 | 0001501697-26-000063 | 10388 | ||||||
| 2026-07-01 | 8-K | 8-K | 5.02,7.01,9.01 | 0001501697-26-000060 | 001-38295 | 261145271 | 34 | 175160 | 1 | 1 |
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-226568 | 005-90199 | 26986554 | 34 | 11494 | |||
| 2026-05-14 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-001669 | 333-295597 | 26990657 | 33 | 1864 | ||
| 2026-05-13 | 8-K/A | 8-K/A | 5.02,5.07,9.01 | 0001501697-26-000051 | 001-38295 | 26974345 | 34 | 311468 | 1 | 1 |
| 2026-05-13 | 4 | FORM 4 | 0001501697-26-000049 | 5659 | ||||||
| 2026-05-12 | 144 | xsl144X01/primary_doc.xml | 0001276750-26-000004 | 001-38295 | 26970215 | 33 | 4777 | |||
| 2026-05-12 | 8-K | 8-K | 5.02,5.07 | 0001501697-26-000047 | 001-38295 | 26968943 | 34 | 309417 | 1 | 1 |
| 2026-05-12 | CORRESP | filename1.htm | 0001501697-26-000046 | 6861 | ||||||
| 2026-05-11 | UPLOAD | filename1.pdf | 0000000000-26-004784 | 333-295597 | 149726 | |||||
| 2026-05-06 | S-3 | S-3 | 0001501697-26-000043 | 333-295597 | 26948409 | 33 | 1539792 | 1 | 1 | |
| 2026-05-06 | 10-Q | 10-Q | 0001501697-26-000040 | 001-38295 | 26945757 | 34 | 6566153 | 1 | 1 | |
| 2026-03-20 | ARS | ARS | 0001501697-26-000033 | 001-38295 | 26776351 | 34 | 48062645 | |||
| 2026-03-20 | DEFA14A | DEFA14A | 0001501697-26-000032 | 001-38295 | 26776327 | 34 | 433219 | |||
| 2026-03-20 | DEF 14A | DEF 14A | 0001501697-26-000031 | 001-38295 | 26776324 | 34 | 3699751 | 1 | 1 | |
| 2026-03-18 | S-8 | S-8 | 0001501697-26-000021 | 333-294391 | 26764387 | 33 | 242720 | 1 | 1 | |
| 2026-03-17 | 10-K | 10-K | 0001501697-26-000018 | 001-38295 | 26759037 | 34 | 11434031 | 1 | 1 | |
| 2026-03-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000895421-26-000094 | 005-90199 | 26731356 | 34 | 13700 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000921895-26-000476 | 005-90199 | 26642224 | 34 | 24828 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001493152-26-007144 | 005-90199 | 26642172 | 34 | 11753 | |||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-26-054779 | 005-90199 | 26642118 | 34 | 173856 | |||
| 2026-02-17 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-26-016241 | 005-90199 | 26639888 | 34 | 13198 | |||
| 2026-02-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-26-015354 | 005-90199 | 26634461 | 34 | 11014 | |||
| 2026-02-12 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000895421-26-000068 | 005-90199 | 26625447 | 34 | 12032 | |||
| 2026-02-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-26-000584 | 005-90199 | 26602218 | 34 | 12123 | |||
| 2026-01-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-26-000246 | 005-90199 | 26535560 | 34 | 12811 | |||
| 2026-01-07 | 4 | FORM 4 | 0001501697-26-000009 | 283428 | ||||||
| 2026-01-05 | 4 | FORM 4 | 0001501697-26-000007 | 284214 | ||||||
| 2026-01-05 | 4 | FORM 4 | 0001501697-26-000006 | 283336 | ||||||
| 2026-01-05 | 4 | FORM 4 | 0001501697-26-000005 | 283698 | ||||||
| 2025-11-14 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-112658 | 005-90199 | 251487459 | 34 | 10968 | |||
| 2025-11-07 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-002923 | 005-90199 | 251461149 | 34 | 11532 | |||
| 2025-11-05 | 10-Q | 10-Q | 0001501697-25-000043 | 001-38295 | 251451922 | 34 | 8006540 | 1 | 1 | |
| 2025-11-05 | 8-K | 8-K | 2.02,9.01 | 0001501697-25-000041 | 001-38295 | 251451884 | 34 | 248227 | 1 | 1 |
| 2025-11-03 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-25-262560 | 005-90199 | 251444166 | 34 | 367483 | |||
| 2025-10-31 | 4 | FORM 4 | 0001339498-25-000004 | 5803 | ||||||
| 2025-10-31 | 4 | FORM 4 | 0002081729-25-000003 | 5770 | ||||||
| 2025-10-31 | 4 | FORM 4 | 0001276750-25-000004 | 5785 | ||||||
| 2025-10-29 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001072613-25-000747 | 005-90199 | 251431423 | 34 | 92183 | |||
| 2025-10-27 | 4 | FORM 4 | 0001501697-25-000035 | 4852 | ||||||
| 2025-10-27 | 8-K | 8-K | 1.01,9.01 | 0001501697-25-000032 | 001-38295 | 251417169 | 34 | 726088 | 1 | 1 |
| 2025-10-24 | 424B5 | 424B5 | 0001501697-25-000031 | 333-273961 | 251416897 | 33 | 491829 | |||
| 2025-10-23 | 424B5 | 424B5 | 0001501697-25-000027 | 333-273961 | 251413192 | 33 | 488125 | |||
| 2025-10-21 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-004474 | 005-90199 | 251405450 | 34 | 17931 | |||
| 2025-10-03 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-096741 | 005-90199 | 251375051 | 34 | 17639 | |||
| 2025-09-18 | 424B3 | 424B3 | 0001501697-25-000024 | 333-290158 | 251323663 | 33 | 203548 | |||
| 2025-09-17 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-002994 | 333-290158 | 251321691 | 33 | 1865 | ||
| 2025-09-17 | 8-K | 8-K | 2.05,5.02,7.01,9.01 | 0001501697-25-000021 | 001-38295 | 251318774 | 34 | 211694 | 1 | 1 |
| 2025-09-15 | CORRESP | filename1.htm | 0001501697-25-000019 | 10467 | ||||||
| 2025-09-15 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-25-203640 | 005-90199 | 251314687 | 34 | 149728 | |||
| 2025-09-15 | UPLOAD | filename1.pdf | 0000000000-25-009968 | 333-290158 | 40211 | |||||
| 2025-09-10 | S-3 | S-3 | 0001501697-25-000017 | 333-290158 | 251306077 | 33 | 345866 | |||
| 2025-09-10 | S-8 | S-8 | 0001501697-25-000016 | 333-290155 | 251306024 | 33 | 88784 | |||
| 2025-08-25 | D | xslFormDX01/primary_doc.xml | 06b | 0001470831-25-000145 | 021-555727 | 251251391 | 33 | 14812 | ||
| 2025-08-25 | 8-K | 8-K | 5.02 | 0001501697-25-000008 | 001-38295 | 251247964 | 34 | 147708 | 1 | 1 |
| 2025-08-20 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000921895-25-002347 | 005-90199 | 251237900 | 34 | 40262 | |||
| 2025-08-19 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-25-003668 | 005-90199 | 251231711 | 34 | 12016 | |||
| 2025-08-18 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001641172-25-024646 | 005-90199 | 251228603 | 34 | 26007 | |||
| 2025-08-18 | SCHEDULE 13D | xslSCHEDULE_13D_X01/primary_doc.xml | 0001104659-25-079821 | 005-90199 | 251228236 | 34 | 34173 | |||
| 2025-08-15 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001072613-25-000643 | 005-90199 | 251225418 | 34 | 94509 | |||
| 2025-08-14 | 4 | FORM 4 | 0001628280-25-040444 | 9405 | ||||||
| 2025-08-14 | 3 | FORM 3 | 0001628280-25-040443 | 9982 | ||||||
| 2025-08-14 | 3 | FORM 3 | 0001628280-25-040442 | 27436 | ||||||
| 2025-08-14 | 4 | FORM 4 | 0001628280-25-040441 | 9436 | ||||||
| 2025-08-14 | 4 | FORM 4 | 0001628280-25-040440 | 9680 | ||||||
| 2025-08-14 | 3 | FORM 3 | 0001628280-25-040439 | 10313 | ||||||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000947871-25-000777 | 005-90199 | 251221439 | 34 | 7594 | |||
| 2025-08-13 | SCHEDULE 13D | xslSCHEDULE_13D_X01/primary_doc.xml | 0000950170-25-108341 | 005-90199 | 251213873 | 34 | 157021 | |||
| 2025-08-13 | 8-K | 8-K | 1.01,3.02,8.01,9.01 | 0001501697-25-000006 | 001-38295 | 251209070 | 34 | 726419 | 1 | 1 |
| 2025-08-12 | 8-K | 8-K | 1.01,3.02,5.02,8.01,9.01 | 0001628280-25-039770 | 001-38295 | 251204165 | 34 | 917288 | 1 | 1 |
| 2025-08-08 | 10-Q | 10-Q | 0001628280-25-039327 | 001-38295 | 251199319 | 34 | 8532804 | 1 | 1 | |
| 2025-07-18 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-003306 | 005-90199 | 251133252 | 34 | 11129 | |||
| 2025-07-03 | 4 | FORM 4 | 0001628280-25-034233 | 5544 | ||||||
| 2025-06-23 | 8-K | 8-K | 1.01,9.01 | 0001628280-25-032627 | 001-38295 | 251065351 | 34 | 736545 | 1 | 1 |
| 2025-06-23 | 424B5 | 424B5 | 0001628280-25-032526 | 333-273961 | 251063014 | 33 | 435419 | |||
| 2025-06-11 | 8-K | 8-K | 5.07 | 0001628280-25-030743 | 001-38295 | 251040217 | 34 | 161721 | 1 | 1 |
| 2025-06-10 | 4 | FORM 4 | 0001628280-25-030504 | 5126 | ||||||
| 2025-06-10 | 4 | FORM 4 | 0001628280-25-030503 | 5107 | ||||||
| 2025-06-10 | 4 | FORM 4 | 0001628280-25-030502 | 5123 | ||||||
| 2025-06-10 | 4 | FORM 4 | 0001628280-25-030500 | 5114 | ||||||
| 2025-06-10 | 4 | FORM 4 | 0001628280-25-030492 | 5072 | ||||||
| 2025-06-10 | 4 | FORM 4 | 0001628280-25-030489 | 5110 | ||||||
| 2025-06-03 | 3 | FORM 3 | 0001628280-25-029175 | 324707 | ||||||
| 2025-06-03 | 4/A | FORM 4/A | 0001628280-25-029113 | 5532 | ||||||
| 2025-05-20 | 4 | FORM 4 | 0001628280-25-026864 | 4911 | ||||||
| 2025-05-01 | 10-Q | 10-Q | 0001628280-25-021358 | 001-38295 | 25899905 | 34 | 8017840 | 1 | 1 | |
| 2025-05-01 | 8-K | 8-K | 2.02,7.01 | 0001628280-25-021304 | 001-38295 | 25899188 | 34 | 5247339 | 1 | 1 |
| 2025-04-25 | DEF 14A | DEF 14A | 0001628280-25-019926 | 001-38295 | 25874857 | 34 | 2571528 | 1 | 1 | |
| 2025-04-25 | DEFA14A | DEFA14A | 0001628280-25-019934 | 001-38295 | 25873980 | 34 | 279507 | |||
| 2025-04-24 | 8-K | 8-K | 5.03,8.01,9.01 | 0001628280-25-019507 | 001-38295 | 25863839 | 34 | 220681 | 1 | 1 |
| 2025-04-18 | 8-K | 8-K | 5.07 | 0001628280-25-018389 | 001-38295 | 25850593 | 34 | 160543 | 1 | 1 |
| 2025-03-26 | S-8 | S-8 | 0001628280-25-014806 | 333-286107 | 25769984 | 33 | 143161 | |||
| 2025-03-26 | 10-K | 10-K | 0001628280-25-014805 | 001-38295 | 25769602 | 34 | 11875709 | 1 | 1 | |
| 2025-03-25 | 8-K | 8-K | 2.02,9.01 | 0001628280-25-014601 | 001-38295 | 25765886 | 34 | 288888 | 1 | 1 |
| 2025-03-24 | DEF 14A | DEF 14A | 0001628280-25-014535 | 001-38295 | 25764717 | 34 | 501655 | |||
| 2025-03-14 | PRE 14A | PRE 14A | 0001628280-25-012815 | 001-38295 | 25740028 | 34 | 496342 | |||
| 2025-03-03 | 8-K | 8-K | 8.01 | 0001628280-25-009490 | 001-38295 | 25699228 | 34 | 158751 | 1 | 1 |
| 2025-02-14 | 4 | FORM 4 | 0001628280-25-005704 | 5329 | ||||||
| 2025-02-14 | 4 | FORM 4 | 0001628280-25-005702 | 5310 | ||||||
| 2025-02-14 | 4 | FORM 4 | 0001628280-25-005700 | 5306 | ||||||
| 2025-02-14 | 4 | FORM 4 | 0001628280-25-005698 | 8371 | ||||||
| 2025-02-14 | 4 | FORM 4 | 0001628280-25-005696 | 5267 | ||||||
| 2025-02-06 | 8-K | 8-K | 2.05,7.01,9.01 | 0001628280-25-004254 | 001-38295 | 25597379 | 34 | 205599 | 1 | 1 |
| 2025-01-31 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000932471-25-000265 | 005-90199 | 25576418 | 34 | 6369 | |||
| 2025-01-27 | 4 | FORM 4 | 0001628280-25-002709 | 7206 | ||||||
| 2025-01-27 | 4 | FORM 4 | 0001628280-25-002708 | 7202 | ||||||
| 2025-01-27 | 4 | FORM 4 | 0001628280-25-002707 | 7189 | ||||||
| 2025-01-27 | 4 | FORM 4 | 0001628280-25-002706 | 7166 | ||||||
| 2025-01-27 | 4 | FORM 4 | 0001628280-25-002705 | 7227 | ||||||
| 2025-01-24 | 144 | xsl144X01/primary_doc.xml | 0001973141-25-000044 | 001-38295 | 25554502 | 33 | 5159 | |||
| 2025-01-24 | 144 | xsl144X01/primary_doc.xml | 0001973141-25-000043 | 001-38295 | 25554494 | 33 | 4488 | |||
| 2025-01-24 | 144 | xsl144X01/primary_doc.xml | 0001973141-25-000041 | 001-38295 | 25554458 | 33 | 4488 | |||
| 2025-01-24 | 144 | xsl144X01/primary_doc.xml | 0001973141-25-000040 | 001-38295 | 25554447 | 33 | 4496 | |||
| 2025-01-24 | 144 | xsl144X01/primary_doc.xml | 0001973141-25-000038 | 001-38295 | 25554318 | 33 | 4568 | |||
| 2025-01-24 | 144 | xsl144X01/primary_doc.xml | 0001973141-25-000037 | 001-38295 | 25554282 | 33 | 4511 | |||
| 2025-01-16 | S-8 | S-8 | 0001628280-25-001740 | 333-284320 | 25536167 | 33 | 115891 | |||
| 2025-01-13 | 8-K | 8-K | 1.01,7.01,9.01 | 0001628280-25-001239 | 001-38295 | 25524842 | 34 | 5575434 | 1 | 1 |
| 2025-01-07 | UPLOAD | filename1.pdf | 0000000000-25-000138 | 001-38295 | 39806 | |||||
| 2024-12-23 | CORRESP | filename1.htm | 0001628280-24-052321 | 321721 | ||||||
| 2024-12-13 | UPLOAD | filename1.pdf | 0000000000-24-013733 | 001-38295 | 43323 | |||||
| 2024-11-19 | 4 | FORM 4 | 0001628280-24-048467 | 5384 | ||||||
| 2024-11-15 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000559 | 001-38295 | 241467973 | 33 | 6310 | |||
| 2024-11-13 | 10-Q | 10-Q | 0001628280-24-047445 | 001-38295 | 241451451 | 34 | 7474993 | 1 | 1 | |
| 2024-11-13 | 8-K | 8-K | 7.01,8.01,9.01 | 0001628280-24-047433 | 001-38295 | 241451286 | 34 | 4407157 | 1 | 1 |
| 2024-11-13 | 8-K | 8-K | 2.02,9.01 | 0001628280-24-047406 | 001-38295 | 241451014 | 34 | 290610 | 1 | 1 |
| 2024-11-12 | SC 13G/A | UnitedStates_13G__X4Pharmace.txt | 0000932471-24-001295 | 005-90199 | 241450333 | 34 | 6674 | |||
| 2024-11-08 | SC 13G | us98420x1037_110824.txt | 0002012383-24-003456 | 005-90199 | 241439584 | 34 | 13728 | |||
| 2024-11-04 | SC 13G/A | UnitedStates_13G__X4Pharmace.txt | 0000932471-24-000783 | 005-90199 | 241422620 | 34 | 5724 | |||
| 2024-10-22 | SC 13G | us98420x1037_102224.txt | 0002012383-24-001574 | 005-90199 | 241387314 | 34 | 13714 | |||
| 2024-10-16 | 4 | FORM 4 | 0001628280-24-042941 | 5387 | ||||||
| 2024-10-15 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000500 | 001-38295 | 241371911 | 33 | 6196 | |||
| 2024-10-08 | 4 | FORM 4 | 0001628280-24-042545 | 7040 | ||||||
| 2024-10-08 | 4 | FORM 4 | 0001628280-24-042544 | 7018 | ||||||
| 2024-10-08 | 4 | FORM 4 | 0001628280-24-042543 | 7039 | ||||||
| 2024-10-08 | 4 | FORM 4 | 0001628280-24-042542 | 6997 | ||||||
| 2024-10-08 | 4 | FORM 4 | 0001628280-24-042541 | 7044 | ||||||
| 2024-10-07 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000493 | 001-38295 | 241358008 | 33 | 5109 | |||
| 2024-10-07 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000492 | 001-38295 | 241358003 | 33 | 4491 | |||
| 2024-10-07 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000490 | 001-38295 | 241357941 | 33 | 4539 | |||
| 2024-10-07 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000489 | 001-38295 | 241357864 | 33 | 4511 | |||
| 2024-10-07 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000488 | 001-38295 | 241357846 | 33 | 4496 | |||
| 2024-10-04 | S-8 | S-8 | 0001628280-24-042323 | 333-282513 | 241355475 | 33 | 103520 | |||
| 2024-09-11 | 4 | FORM 4 | 0001628280-24-040128 | 5450 | ||||||
| 2024-09-09 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000445 | 001-38295 | 241287309 | 33 | 4477 | |||
| 2024-08-16 | 8-K | 8-K | 3.01 | 0001628280-24-037546 | 001-38295 | 241216648 | 34 | 158958 | 1 | 1 |
| 2024-08-09 | 8-K | 8-K | 7.01 | 0001628280-24-036495 | 001-38295 | 241193199 | 34 | 155651 | 1 | 1 |
| 2024-08-08 | 10-Q | 10-Q | 0001628280-24-036127 | 001-38295 | 241188310 | 34 | 21572966 | 1 | 1 | |
| 2024-08-08 | 8-K | 8-K | 2.02,9.01 | 0001628280-24-035848 | 001-38295 | 241185899 | 34 | 290990 | 1 | 1 |
| 2024-07-19 | 8-K | 8-K | 7.01 | 0001628280-24-032266 | 001-38295 | 241126125 | 34 | 155624 | 1 | 1 |
| 2024-06-27 | 8-K | 8-K | 7.01,8.01,9.01 | 0001628280-24-030243 | 001-38295 | 241075400 | 34 | 4654106 | 1 | 1 |
| 2024-06-11 | 8-K | 8-K | 5.07 | 0001628280-24-027680 | 001-38295 | 241035919 | 34 | 172427 | 1 | 1 |
| 2024-06-11 | 4 | FORM 4 | 0001628280-24-027678 | 5116 | ||||||
| 2024-06-11 | 4 | FORM 4 | 0001628280-24-027677 | 5122 | ||||||
| 2024-06-11 | 4 | FORM 4 | 0001628280-24-027676 | 5081 | ||||||
| 2024-06-11 | 4 | FORM 4 | 0001628280-24-027675 | 5136 | ||||||
| 2024-06-11 | 4 | FORM 4 | 0001628280-24-027674 | 5132 | ||||||
| 2024-06-11 | 4 | FORM 4 | 0001628280-24-027673 | 5124 | ||||||
| 2024-06-11 | 4 | FORM 4 | 0001628280-24-027672 | 5186 | ||||||
| 2024-06-11 | 4 | FORM 4 | 0001628280-24-027671 | 5120 | ||||||
| 2024-05-22 | 8-K | 8-K | 7.01,9.01 | 0001628280-24-024633 | 001-38295 | 24971676 | 34 | 4409141 | 1 | 1 |
| 2024-05-09 | 8-K | 8-K | 1.01,2.01,5.02,7.01,8.01,9.01 | 0001628280-24-021937 | 001-38295 | 24928451 | 34 | 199827 | 1 | 1 |
| 2024-05-07 | 10-Q | 10-Q | 0001628280-24-021120 | 001-38295 | 24922370 | 34 | 5910883 | 1 | 1 | |
| 2024-05-07 | 8-K | 8-K | 2.02,9.01 | 0001628280-24-020827 | 001-38295 | 24919485 | 34 | 244716 | 1 | 1 |
| 2024-04-29 | ARS | ARS | 0001628280-24-019063 | 001-38295 | 24892234 | 34 | 46715218 | |||
| 2024-04-29 | DEFA14A | DEFA14A | 0001628280-24-019058 | 001-38295 | 24892176 | 34 | 274541 | |||
| 2024-04-29 | DEF 14A | DEF 14A | 0001628280-24-019056 | 001-38295 | 24892153 | 34 | 1398967 | |||
| 2024-04-29 | 8-K | 8-K | 7.01,8.01,9.01 | 0001628280-24-018793 | 001-38295 | 24886748 | 34 | 3938092 | 1 | 1 |
| 2024-04-29 | 8-K | 8-K | 7.01,8.01,9.01 | 0001628280-24-018773 | 001-38295 | 24886456 | 34 | 233494 | 1 | 1 |
| 2024-04-05 | 8-K | 8-K | 8.01 | 0001628280-24-015059 | 001-38295 | 24826907 | 34 | 155844 | 1 | 1 |
| 2024-04-01 | 8-K | 8-K | 7.01 | 0001628280-24-013896 | 001-38295 | 24805929 | 34 | 155666 | 1 | 1 |
| 2024-03-21 | 10-K | 10-K | 0001628280-24-012578 | 001-38295 | 24772234 | 34 | 9912956 | 1 | 1 | |
| 2024-03-21 | 8-K | 8-K | 2.02 | 0001628280-24-012372 | 001-38295 | 24769471 | 34 | 276759 | 1 | 1 |
| 2024-03-11 | 4 | FORM 4 | 0001628280-24-010281 | 5497 | ||||||
| 2024-03-11 | 4 | FORM 4 | 0001628280-24-010280 | 5486 | ||||||
| 2024-03-11 | 4 | FORM 4 | 0001628280-24-010279 | 5306 | ||||||
| 2024-03-11 | 4 | FORM 4 | 0001628280-24-010278 | 5445 | ||||||
| 2024-03-11 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000169 | 001-38295 | 24738243 | 33 | 5123 | |||
| 2024-03-11 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000168 | 001-38295 | 24738077 | 33 | 5116 | |||
| 2024-03-11 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000167 | 001-38295 | 24737949 | 33 | 5115 | |||
| 2024-03-11 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000166 | 001-38295 | 24737942 | 33 | 5160 | |||
| 2024-02-28 | 4/A | FORM 4/A | 0001628280-24-007711 | 6199 | ||||||
| 2024-02-16 | 4 | FORM 4 | 0001628280-24-005385 | 5737 | ||||||
| 2024-02-16 | 4 | FORM 4 | 0001628280-24-005384 | 5718 | ||||||
| 2024-02-16 | 4 | FORM 4 | 0001628280-24-005383 | 5674 | ||||||
| 2024-02-16 | 4 | FORM 4 | 0001628280-24-005382 | 5715 | ||||||
| 2024-02-16 | 4 | FORM 4 | 0001628280-24-005380 | 5698 | ||||||
| 2024-02-16 | 4 | FORM 4 | 0001628280-24-005379 | 5721 | ||||||
| 2024-02-14 | SC 13G/A | AMENDMENT NO. 4 | 0000947871-24-000161 | 005-90199 | 24641506 | 34 | 69832 | |||
| 2024-02-14 | SC 13G | p24-0888sc13g.htm | 0000902664-24-001745 | 005-90199 | 24639599 | 34 | 117976 | |||
| 2024-02-14 | SC 13G/A | SCHEDULE 13G/A | 0001104659-24-023820 | 005-90199 | 24639216 | 34 | 116672 | |||
| 2024-02-13 | SC 13G/A | SC 13G/A | 0001193125-24-034104 | 005-90199 | 24630915 | 34 | 148179 | |||
| 2024-02-12 | 4 | FORM 4 | 0001628280-24-004288 | 5443 | ||||||
| 2024-02-12 | 4 | FORM 4 | 0001628280-24-004287 | 5490 | ||||||
| 2024-02-12 | 4 | FORM 4 | 0001628280-24-004266 | 5560 | ||||||
| 2024-02-12 | 4 | FORM 4 | 0001628280-24-004263 | 5382 | ||||||
| 2024-02-12 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000107 | 001-38295 | 24620400 | 33 | 4489 | |||
| 2024-02-12 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000106 | 001-38295 | 24620389 | 33 | 4494 | |||
| 2024-02-12 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000103 | 001-38295 | 24619908 | 33 | 4476 | |||
| 2024-02-12 | 144 | xsl144X01/primary_doc.xml | 0001973141-24-000098 | 001-38295 | 24619778 | 33 | 4531 | |||
| 2024-02-07 | SC 13G/A | us98420x1037_020724.txt | 0001086364-24-006819 | 005-90199 | 24605683 | 34 | 12551 | |||
| 2024-01-31 | SC 13G | us98420x1037_013124.txt | 0001086364-24-006042 | 005-90199 | 24582142 | 34 | 13416 | |||
| 2024-01-25 | S-8 | S-8 | 0001628280-24-002243 | 333-276691 | 24562474 | 33 | 98933 | |||
| 2024-01-16 | SC 13G/A | XFOR_SC13GA1.htm | 0001273087-24-000017 | 005-90199 | 24535389 | 34 | 81817 | |||
| 2024-01-08 | 8-K | 8-K | 7.01 | 0001628280-24-000843 | 001-38295 | 24520153 | 34 | 158727 | 1 | 1 |
| 2024-01-08 | SC 13G/A | X4 PHARMACEUTICALS, INC. | 0000902664-24-000073 | 005-90199 | 24518808 | 34 | 78090 | |||
| 2023-11-27 | 8-K | 8-K | 7.01 | 0001628280-23-040050 | 001-38295 | 231441101 | 34 | 158681 | 1 | 1 |
| 2023-11-14 | 8-K | 8-K | 3.01 | 0001628280-23-038936 | 001-38295 | 231406219 | 34 | 162021 | 1 | 1 |
| 2023-11-09 | 10-Q | 10-Q | 0001628280-23-038334 | 001-38295 | 231393715 | 34 | 7282635 | 1 | 1 | |
| 2023-11-09 | 8-K | 8-K | 2.02 | 0001628280-23-038053 | 001-38295 | 231390168 | 34 | 284842 | 1 | 1 |
| 2023-11-03 | 4 | FORM 4 | 0001628280-23-036796 | 7461 | ||||||
| 2023-11-03 | 4 | FORM 4 | 0001628280-23-036758 | 5317 | ||||||
| 2023-11-03 | 4 | FORM 4 | 0001628280-23-036757 | 5452 | ||||||
| 2023-11-03 | 4 | FORM 4 | 0001628280-23-036756 | 5476 | ||||||
| 2023-11-03 | 4 | FORM 4 | 0001628280-23-036755 | 5499 | ||||||
| 2023-11-03 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000278 | 001-38295 | 231376232 | 33 | 5044 | |||
| 2023-11-02 | 4 | FORM 4 | 0001628280-23-036471 | 4961 | ||||||
| 2023-11-02 | 4 | FORM 4 | 0001628280-23-036466 | 4939 | ||||||
| 2023-11-02 | 4 | FORM 4 | 0001628280-23-036463 | 4964 | ||||||
| 2023-11-02 | 4 | FORM 4 | 0001628280-23-036462 | 4956 | ||||||
| 2023-11-02 | 4 | FORM 4 | 0001628280-23-036459 | 4917 | ||||||
| 2023-11-01 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000269 | 001-38295 | 231368168 | 33 | 4453 | |||
| 2023-11-01 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000268 | 001-38295 | 231368146 | 33 | 5036 | |||
| 2023-11-01 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000266 | 001-38295 | 231368109 | 33 | 4449 | |||
| 2023-11-01 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000265 | 001-38295 | 231368099 | 33 | 4419 | |||
| 2023-11-01 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000264 | 001-38295 | 231368076 | 33 | 4468 | |||
| 2023-10-31 | 8-K | 8-K | 8.01 | 0001628280-23-035729 | 001-38295 | 231364860 | 34 | 202607 | 1 | 1 |
| 2023-10-18 | 4 | FORM 4 | 0001628280-23-034579 | 4842 | ||||||
| 2023-10-18 | 3 | FORM 3 | 0001628280-23-034577 | 355618 | ||||||
| 2023-10-18 | 8-K | 8-K | 5.02,7.01 | 0001628280-23-034547 | 001-38295 | 231330967 | 34 | 200898 | 1 | 1 |
| 2023-09-12 | 4 | FORM 4 | 0001628280-23-032065 | 5346 | ||||||
| 2023-09-08 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000210 | 001-38295 | 231245248 | 33 | 6285 | |||
| 2023-09-05 | 8-K | 8-K | 8.01 | 0001628280-23-031405 | 001-38295 | 231236683 | 34 | 218862 | 1 | 1 |
| 2023-09-05 | 4 | FORM 4 | 0001628280-23-031389 | 5623 | ||||||
| 2023-08-24 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2023-08-24 16:00:00 | 9999999995-23-002489 | 333-273961 | 231203719 | 33 | 1823 | ||
| 2023-08-22 | 4 | FORM 4 | 0001628280-23-030224 | 5171 | ||||||
| 2023-08-22 | CORRESP | filename1.htm | 0001628280-23-030216 | 10059 | ||||||
| 2023-08-21 | UPLOAD | filename1.pdf | 0000000000-23-009115 | 40371 | ||||||
| 2023-08-16 | 3 | FORM 3 SUBMISSION | 0001209191-23-046012 | 6851 | ||||||
| 2023-08-14 | S-3 | S-3 | 0001628280-23-029155 | 333-273961 | 231165841 | 33 | 816393 | |||
| 2023-08-14 | S-8 | S-8 | 0001628280-23-029154 | 333-273960 | 231165839 | 33 | 262307 | |||
| 2023-08-11 | 4 | FORM 4 | 0001628280-23-029148 | 7002 | ||||||
| 2023-08-10 | 10-Q | 10-Q | 0001628280-23-028897 | 001-38295 | 231160120 | 34 | 7740328 | 1 | 1 | |
| 2023-08-10 | 8-K | 8-K | 2.02 | 0001628280-23-028730 | 001-38295 | 231157101 | 34 | 296149 | 1 | 1 |
| 2023-08-03 | 8-K | 8-K | 1.01,2.03,7.01 | 0001628280-23-027303 | 001-38295 | 231140829 | 34 | 214348 | 1 | 1 |
| 2023-07-05 | 4 | FORM 4 | 0001628280-23-024229 | 5343 | ||||||
| 2023-07-05 | 4 | FORM 4 | 0001628280-23-024228 | 5334 | ||||||
| 2023-06-30 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000116 | 001-38295 | 231061444 | 33 | 5615 | |||
| 2023-06-30 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000115 | 001-38295 | 231061377 | 33 | 5721 | |||
| 2023-06-26 | 4 | FORM 4 | 0001628280-23-023445 | 5348 | ||||||
| 2023-06-26 | 4 | FORM 4 | 0001628280-23-023443 | 5334 | ||||||
| 2023-06-26 | 4 | FORM 4 | 0001628280-23-023440 | 5384 | ||||||
| 2023-06-23 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000106 | 001-38295 | 231037505 | 33 | 4988 | |||
| 2023-06-23 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000105 | 001-38295 | 231037449 | 33 | 5662 | |||
| 2023-06-23 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000104 | 001-38295 | 231037416 | 33 | 5093 | |||
| 2023-06-21 | 424B3 | 424B3 | 0001193125-23-170302 | 333-272551 | 231026627 | 33 | 240175 | |||
| 2023-06-20 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2023-06-20 16:00:00 | 9999999995-23-001801 | 333-272551 | 231027343 | 33 | 1823 | ||
| 2023-06-16 | 4 | FORM 4 | 0001628280-23-022480 | 5343 | ||||||
| 2023-06-16 | 4 | FORM 4 | 0001628280-23-022473 | 5318 | ||||||
| 2023-06-16 | 4 | FORM 4 | 0001628280-23-022469 | 5384 | ||||||
| 2023-06-16 | CORRESP | filename1.htm | 0001628280-23-022467 | 11684 | ||||||
| 2023-06-16 | SC 13G | XFOR_SC13G.htm | 0001273087-23-000117 | 005-90199 | 231020931 | 34 | 81719 | |||
| 2023-06-16 | UPLOAD | filename1.pdf | 0000000000-23-006515 | 40227 | ||||||
| 2023-06-15 | 8-K | 8-K | 5.07 | 0001628280-23-022266 | 001-38295 | 231017948 | 34 | 204645 | 1 | 1 |
| 2023-06-15 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000092 | 001-38295 | 231017920 | 33 | 5148 | |||
| 2023-06-15 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000090 | 001-38295 | 231017245 | 33 | 4361 | |||
| 2023-06-15 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000089 | 001-38295 | 231017217 | 33 | 4447 | |||
| 2023-06-14 | 4 | FORM 4 | 0001628280-23-022099 | 5043 | ||||||
| 2023-06-14 | 4 | FORM 4 | 0001628280-23-022096 | 5052 | ||||||
| 2023-06-14 | 4 | FORM 4 | 0001628280-23-022093 | 5001 | ||||||
| 2023-06-14 | 4 | FORM 4 | 0001628280-23-022091 | 5039 | ||||||
| 2023-06-14 | 4 | FORM 4 | 0001628280-23-022090 | 5036 | ||||||
| 2023-06-14 | 4 | FORM 4 | 0001628280-23-022084 | 5106 | ||||||
| 2023-06-09 | S-3 | S-3 | 0001628280-23-021708 | 333-272551 | 231005389 | 33 | 360647 | |||
| 2023-06-01 | D | xslFormDX01/primary_doc.xml | 06b | 0001231919-23-000037 | 021-483142 | 23985291 | 33 | 19899 | ||
| 2023-06-01 | 8-K | 8-K | 7.01 | 0001628280-23-020502 | 001-38295 | 23984861 | 34 | 177773 | 1 | 1 |
| 2023-05-31 | 4 | FORM 4 | 0001628280-23-020355 | 5433 | ||||||
| 2023-05-31 | 144 | xsl144X01/primary_doc.xml | 0001973141-23-000060 | 001-38295 | 23980781 | 33 | 5149 | |||
| 2023-05-26 | SC 13D/A | GROWTH EQUITY OPPORTUNITIES 18 VGE, LLC / X4 PHARMACEUTICALS, INC. -- SCHEDULE 1 | 0001072613-23-000346 | 005-90199 | 23967683 | 34 | 460146 | |||
| 2023-05-16 | 8-K | 8-K | 1.01,3.02,7.01,8.01 | 0001628280-23-018424 | 001-38295 | 23927874 | 34 | 4772684 | 1 | 1 |
| 2023-05-04 | 10-Q | 10-Q | 0001628280-23-015763 | 001-38295 | 23889054 | 34 | 7256056 | 1 | 1 | |
| 2023-05-04 | 8-K | 8-K | 7.01 | 0001628280-23-015714 | 001-38295 | 23888688 | 34 | 177769 | 1 | 1 |
| 2023-05-04 | 8-K | 8-K | 2.02,9.01 | 0001628280-23-015494 | 001-38295 | 23886795 | 34 | 298856 | 1 | 1 |
| 2023-05-04 | 8-K | 8-K | 2.01,9.01 | 0001628280-23-015415 | 001-38295 | 23886314 | 34 | 298828 | 1 | 1 |
| 2023-04-27 | DEFA14A | DEFA14A | 0001628280-23-013590 | 001-38295 | 23857364 | 34 | 16493 | |||
| 2023-04-25 | ARS | ARS | 0001628280-23-012964 | 001-38295 | 23845378 | 34 | 1808830 | |||
| 2023-04-25 | DEFA14A | DEFA14A | 0001628280-23-012944 | 001-38295 | 23845185 | 34 | 437865 | |||
| 2023-04-25 | DEF 14A | DEF 14A | 0001628280-23-012932 | 001-38295 | 23844974 | 34 | 1285884 | |||
| 2023-03-21 | 8-K | 8-K | 7.01 | 0001628280-23-008761 | 001-38295 | 23750360 | 34 | 161423 | 1 | 1 |
| 2023-03-21 | 10-K | 10-K | 0001628280-23-008745 | 001-38295 | 23749941 | 34 | 36036716 | 1 | 1 | |
| 2023-03-21 | 8-K | 8-K | 2.02 | 0001628280-23-008677 | 001-38295 | 23747831 | 34 | 294465 | 1 | 1 |
| 2023-03-13 | 4 | FORM 4 | 0001628280-23-007724 | 5353 | ||||||
| 2023-03-13 | 4 | FORM 4 | 0001628280-23-007722 | 5323 | ||||||
| 2023-03-13 | 4 | FORM 4 | 0001628280-23-007721 | 5399 | ||||||
| 2023-03-13 | 4 | FORM 4 | 0001628280-23-007720 | 5393 | ||||||
| 2023-03-10 | 8-K | 8-K | 8.01 | 0001628280-23-007516 | 001-38295 | 23723596 | 34 | 178158 | 1 | 1 |
| 2023-02-15 | 4 | FORM 4 | 0001628280-23-003759 | 5398 | ||||||
| 2023-02-15 | 4 | FORM 4 | 0001628280-23-003758 | 5353 | ||||||
| 2023-02-15 | 4 | FORM 4 | 0001628280-23-003757 | 5314 | ||||||
| 2023-02-15 | 4 | FORM 4 | 0001628280-23-003755 | 5402 | ||||||
| 2023-02-14 | SC 13G/A | AMENDMENT NO. 3 | 0000947871-23-000194 | 005-90199 | 23631855 | 34 | 72483 | |||
| 2023-02-14 | SC 13G/A | SCHEDULE 13G/A, AMENDMENT #2 | 0000899140-23-000393 | 005-90199 | 23629627 | 34 | 44402 | |||
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001193125-23-037932 | 005-90199 | 23624760 | 34 | 68118 | |||
| 2023-02-14 | SC 13G/A | SC 13G/A | 0001193125-23-037002 | 005-90199 | 23622087 | 34 | 140712 | |||
| 2023-02-14 | SC 13G/A | AMENDMENT NO. 4 TO THE SCHEDULE 13G | 0000921895-23-000465 | 005-90199 | 23620468 | 34 | 280468 | |||
| 2023-01-20 | S-8 | S-8 | 0001628280-23-001353 | 333-269335 | 23541540 | 33 | 133201 | |||
| 2023-01-13 | SC 13G | X4 PHARMACEUTICALS, INC. | 0000902664-23-000237 | 005-90199 | 23527305 | 34 | 84036 | |||
| 2023-01-06 | 8-K | 8-K | 1.01,2.03 | 0001628280-23-000666 | 001-38295 | 23516023 | 34 | 186737 | 1 | 1 |
| 2023-01-05 | 8-K | 8-K | 7.01 | 0001628280-23-000455 | 001-38295 | 23511378 | 34 | 177710 | 1 | 1 |
| 2022-12-23 | 8-K | 8-K | 5.02,9.01 | 0001193125-22-311765 | 001-38295 | 221485332 | 34 | 228062 | 1 | 1 |
| 2022-12-20 | SC 13D/A | GROWTH EQUITY OPPORTUNITIES 18 VGE, LLC / X4 PHARMACEUTICALS, INC. -- SCHEDULE 1 | 0001072613-22-000662 | 005-90199 | 221472199 | 34 | 510893 | |||
| 2022-12-09 | 8-K | 8-K | 1.01,8.01 | 0001628280-22-031632 | 001-38295 | 221453722 | 34 | 980663 | 1 | 1 |
| 2022-12-09 | 424B5 | 424B5 | 0001193125-22-301149 | 333-249544 | 221453320 | 33 | 659955 | |||
| 2022-12-07 | 424B5 | 424B5 | 0001193125-22-299607 | 333-249544 | 221449022 | 33 | 662105 | |||
| 2022-11-29 | 8-K | 8-K | 7.01,8.01 | 0001628280-22-030943 | 001-38295 | 221432814 | 34 | 2753705 | 1 | 1 |
| 2022-11-09 | 4 | FORM 4 | 0001628280-22-029265 | 5603 | ||||||
| 2022-11-09 | 4 | FORM 4 | 0001628280-22-029261 | 5617 | ||||||
| 2022-11-09 | 4 | FORM 4 | 0001628280-22-029260 | 5650 | ||||||
| 2022-11-09 | 4 | FORM 4 | 0001628280-22-029259 | 5642 | ||||||
| 2022-11-09 | 8-K | 8-K | 5.02 | 0001628280-22-029252 | 001-38295 | 221372910 | 34 | 275117 | 1 | 1 |
| 2022-11-04 | 4 | FORM 4 | 0001628280-22-028462 | 5592 | ||||||
| 2022-11-04 | 3 | FORM 3 | 0001628280-22-028460 | 6944 | ||||||
| 2022-11-03 | 10-Q | 10-Q | 0001628280-22-028201 | 001-38295 | 221358190 | 34 | 7424500 | 1 | 1 | |
| 2022-11-03 | 8-K | 8-K | 2.02,8.01 | 0001628280-22-027967 | 001-38295 | 221356211 | 34 | 326171 | 1 | 1 |
| 2022-10-04 | 8-K | 8-K | 7.01,8.01 | 0001628280-22-025971 | 001-38295 | 221292413 | 34 | 311602 | 1 | 1 |
| 2022-09-27 | 8-K | 8-K | 7.01,8.01 | 0001628280-22-025519 | 001-38295 | 221267281 | 34 | 4557393 | 1 | 1 |
| 2022-09-01 | 8-K | 8-K | 3.03,5.03,5.07 | 0001628280-22-024161 | 001-38295 | 221221513 | 34 | 3062911 | 1 | 1 |
| 2022-08-19 | 4 | FORM 4 | 0001628280-22-023326 | 5302 | ||||||
| 2022-08-19 | 4 | FORM 4 | 0001628280-22-023325 | 5326 | ||||||
| 2022-08-19 | 4 | FORM 4 | 0001628280-22-023324 | 5547 | ||||||
| 2022-08-19 | 4 | FORM 4 | 0001628280-22-023323 | 5300 | ||||||
| 2022-08-11 | DEF 14A | DEF 14A | 0001193125-22-218580 | 001-38295 | 221156229 | 34 | 456702 | |||
| 2022-08-05 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2022-08-05 16:00:00 | 9999999995-22-002280 | 333-266410 | 221142391 | 33 | 1823 | ||
| 2022-08-05 | 424B3 | 424B3 | 0001193125-22-213712 | 333-266410 | 221141629 | 33 | 189453 | |||
| 2022-08-05 | 8-K | 8-K | 7.01 | 0001628280-22-021240 | 001-38295 | 221138673 | 34 | 4295619 | 1 | 1 |
| 2022-08-04 | 10-Q | 10-Q | 0001628280-22-021070 | 001-38295 | 221136648 | 34 | 6702611 | 1 | 1 | |
| 2022-08-04 | 8-K | 8-K | 2.02 | 0001628280-22-020859 | 001-38295 | 221134693 | 34 | 303578 | 1 | 1 |
| 2022-08-03 | CORRESP | filename1.htm | 0001193125-22-210648 | 8234 | ||||||
| 2022-08-02 | UPLOAD | filename1.pdf | 0000000000-22-008144 | 40273 | ||||||
| 2022-08-01 | PRE 14A | PRE 14A | 0001193125-22-208632 | 001-38295 | 221124702 | 34 | 456863 | |||
| 2022-07-29 | S-3 | S-3 | 0001193125-22-206657 | 333-266410 | 221121088 | 33 | 292708 | |||
| 2022-07-29 | 8-K | 8-K | 5.02 | 0001193125-22-206598 | 001-38295 | 221120774 | 34 | 146140 | 1 | 1 |
| 2022-07-29 | 424B3 | 424B3 | 0001628280-22-019770 | 333-264459 | 221117368 | 33 | 113667 | |||
| 2022-07-19 | SC 13D | GROWTH EQUITY OPPORTUNITIES 18 VGE, LLC / X4 PHARMACEUTICALS, INC. -- SCHEDULE 1 | 0001072613-22-000489 | 005-90199 | 221092304 | 34 | 510110 | |||
| 2022-07-19 | D | xslFormDX01/primary_doc.xml | 06b | 0001231919-22-000047 | 021-452949 | 221091760 | 33 | 17797 | ||
| 2022-07-01 | 4 | FORM 4 | 0001628280-22-018400 | 5297 | ||||||
| 2022-07-01 | 4 | FORM 4 | 0001628280-22-018397 | 5324 | ||||||
| 2022-07-01 | 8-K | 8-K | 1.01,2.03,3.02,8.01 | 0001628280-22-018392 | 001-38295 | 221061952 | 34 | 1090960 | 1 | 1 |
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018055 | 5075 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018054 | 5133 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018052 | 5062 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018051 | 5056 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018050 | 5078 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018048 | 5067 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018047 | 5297 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018045 | 5024 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018044 | 5500 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018043 | 5544 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001628280-22-018042 | 5300 | ||||||
| 2022-06-17 | 4 | FORM 4 | 0001628280-22-017438 | 5297 | ||||||
| 2022-06-17 | 4 | FORM 4 | 0001628280-22-017436 | 5363 | ||||||
| 2022-06-17 | 4 | FORM 4 | 0001628280-22-017435 | 5322 | ||||||
| 2022-06-17 | 4 | FORM 4 | 0001628280-22-017433 | 5300 | ||||||
| 2022-06-07 | 8-K | 8-K | 5.07 | 0001628280-22-016443 | 001-38295 | 221001210 | 34 | 190038 | 1 | 1 |
| 2022-06-06 | 4 | FORM 4 | 0001628280-22-016336 | 5583 | ||||||
| 2022-05-20 | 8-K | 8-K | 7.01,8.01 | 0001628280-22-015040 | 001-38295 | 22947721 | 34 | 183489 | 1 | 1 |
| 2022-05-13 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2022-05-13 16:00:00 | 9999999995-22-001472 | 333-264459 | 22925138 | 33 | 1822 | ||
| 2022-05-12 | 10-Q | 10-Q | 0001628280-22-014095 | 001-38295 | 22918219 | 34 | 6473358 | 1 | 1 | |
| 2022-05-12 | CORRESP | filename1.htm | 0001193125-22-148609 | 7884 | ||||||
| 2022-05-12 | 8-K | 8-K | 2.02,7.01 | 0001628280-22-013956 | 001-38295 | 22915766 | 34 | 285237 | 1 | 1 |
| 2022-04-28 | UPLOAD | filename1.pdf | 0000000000-22-004554 | 40300 | ||||||
| 2022-04-25 | DEFA14A | DEFA14A | 0001628280-22-010147 | 001-38295 | 22850580 | 34 | 473129 | |||
| 2022-04-25 | DEF 14A | DEF 14A | 0001628280-22-010145 | 001-38295 | 22850574 | 34 | 945719 | |||
| 2022-04-22 | S-3 | S-3 | 0001628280-22-010034 | 333-264459 | 22846681 | 33 | 287104 | |||
| 2022-03-22 | 424B5 | 424B5 | 0001628280-22-006888 | 333-242372 | 22759643 | 33 | 54413 | |||
| 2022-03-17 | 10-K | 10-K | 0001628280-22-006547 | 001-38295 | 22748688 | 34 | 11055845 | 1 | 1 | |
| 2022-03-17 | 8-K | 8-K | 2.02,7.01 | 0001628280-22-006482 | 001-38295 | 22746850 | 34 | 312238 | 1 | 1 |
| 2022-03-10 | S-8 | S-8 | 0001628280-22-005734 | 333-263430 | 22729634 | 33 | 132096 |
One latest value per concept from companyfacts (398 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 102.11M | 2026-11-02 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 14.90M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 25,922.79 | 2026-05-06 | S-3 | 2026-05-06 | 0001501697-26-000043 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 25,922.79 | 2026-05-06 | S-3 | 2026-05-06 | 0001501697-26-000043 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 300.00M | 2026-05-06 | S-3 | 2026-05-06 | 0001501697-26-000043 | |||
| us-gaap | AcceleratedShareRepurchasesInitialPricePaidPerShare | Accelerated Share Repurchases, Initial Price Paid Per Share | USD/shares | 2.17 | 2022-01-14 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | AccountsAndOtherReceivablesNetCurrent | Accounts and Other Receivables, Net, Current | USD | 1.47M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 4.88M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 1.47M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 8.97M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 984,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AccruedRoyaltiesCurrent | Accrued Royalties, Current | USD | 3.09M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | AccruedRoyaltiesCurrentAndNoncurrent | Accrued Royalties | USD | 110,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 1.39M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 789.93M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AdjustmentForAmortization | Amortization | USD | 289,000 | 2025-01-01 | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-01 | 0001628280-25-021358 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalMarkToMarket | Adjustments to Additional Paid in Capital, Fair Value | USD | 817,000 | 2019-01-01 | 2019-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 3.50M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 3.50M | 2021-04-01 | 2021-06-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001628280-21-021795 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 9.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | AmortizationOfIntangibleAssets | Amortization of Intangible Assets | USD | 600,000 | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-05 | 0001501697-25-000043 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 18.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | AssetAcquisitionConsiderationTransferredOtherAssets | AssetAcquisitionConsiderationTransferredOtherAssets | USD | 5.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | Assets | Assets | USD | 231.82M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 198.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 159.79M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 1.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 1.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued | Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares | 2.44M | 2019-03-13 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001628280-19-013715 | |
| us-gaap | BusinessAcquisitionPercentageOfVotingInterestsAcquired | Business Acquisition, Percentage of Voting Interests Acquired | pure | 0.64 | 2019-03-13 | 2020 | FY | 10-K | 2021-03-19 | 0001628280-21-005202 | |
| us-gaap | BusinessAcquisitionsProFormaNetIncomeLoss | Business Acquisition, Pro Forma Net Income (Loss) | USD | -57.82M | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 |
| us-gaap | BusinessAcquisitionsProFormaRevenue | Business Acquisition, Pro Forma Revenue | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 |
| us-gaap | BusinessCombinationAcquisitionRelatedCosts | Business Combination, Acquisition Related Costs | USD | 1.00M | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 205,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | CapitalizedContractCostAmortization | Capitalized Contract Cost, Amortization | USD | 3.30M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | CapitalizedContractCostGross | Capitalized Contract Cost, Gross | USD | 4.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | CapitalizedContractCostNet | Capitalized Contract Cost, Net | USD | 700,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | CapitalizedContractCostNetCurrent | Capitalized Contract Cost, Net, Current | USD | 200,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | CapitalizedContractCostNetNoncurrent | Capitalized Contract Cost, Net, Noncurrent | USD | 500,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | CapitalLeaseObligationsIncurred | Lease Obligation Incurred | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | CashAcquiredFromAcquisition | Cash Acquired from Acquisition | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 185.80M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | CashAndCashEquivalentsFairValueDisclosure | Cash and Cash Equivalents, Fair Value Disclosure | USD | 123.84M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 187.70M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 186.48M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -31.38M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 0.03 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights | Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 15.24M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 37.92M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 2.73M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 500.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 100.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 100.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 101,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -37.45M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | ContractWithCustomerLiability | Contract with Customer, Liability | USD | 1.33M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice | Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price | USD | 401,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ContractWithCustomerLiabilityCurrent | Contract with Customer, Liability, Current | USD | 938,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ContractWithCustomerLiabilityNoncurrent | Contract with Customer, Liability, Noncurrent | USD | 391,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ContractWithCustomerLiabilityRevenueRecognized | Contract with Customer, Liability, Revenue Recognized | USD | -157,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ConvertibleDebt | Convertible Debt | USD | 0 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | CostOfRevenue | Cost of Revenue | USD | 2.73M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | CostsAndExpenses | Costs and Expenses | USD | 38.96M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | CurrentFederalTaxExpenseBenefit | Current Federal Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | CurrentForeignTaxExpenseBenefit | Current Foreign Tax Expense (Benefit) | USD | 28,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 13,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | DebtInstrumentCarryingAmount | Long-term Debt, Gross | USD | 9.74M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | DebtInstrumentPeriodicPaymentPrincipal | Debt Instrument, Periodic Payment, Principal | USD | 2.10M | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | DebtInstrumentUnamortizedDiscount | Debt Instrument, Unamortized Discount | USD | 317,000 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-19 | 0001628280-21-005202 | |
| us-gaap | DebtInstrumentUnamortizedDiscountCurrent | Debt Instrument, Unamortized Discount, Current | USD | 19,000 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | DebtInstrumentUnamortizedDiscountNoncurrent | Debt Instrument, Unamortized Discount, Noncurrent | USD | 1.84M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | DebtInstrumentUnamortizedDiscountPremiumNet | Debt Instrument, Unamortized Discount (Premium), Net | USD | 215,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | DebtInstrumentUnamortizedPremium | Debt Instrument, Unamortized Premium | USD | 223,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-19 | 0001628280-21-005202 | |
| us-gaap | DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 399,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 3.50M | 2021-03-23 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001628280-21-021795 | |
| us-gaap | DeferredRentCreditCurrent | Deferred Rent Credit, Current | USD | 93,000 | 2018-12-31 | 2019 | Q1 | 10-Q | 2019-05-15 | 0001193125-19-148119 | |
| us-gaap | DeferredRentCreditNoncurrent | Deferred Rent Credit, Noncurrent | USD | 417,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 214.58M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 399,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 129.94M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 3.58M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwards | Deferred Tax Assets, Tax Credit Carryforwards | USD | 25.16M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness | Deferred Tax Assets, Tax Credit Carryforwards, General Business | USD | 7.75M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 18.65M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | USD | 1.46M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 214.19M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | DefinedContributionPlanCostRecognized | Defined Contribution Plan, Cost | USD | 0 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | Depreciation | Depreciation | USD | 125,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | DepreciationDepletionAndAmortization | Depreciation, Depletion and Amortization | USD | 1.55M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | DerivativeFairValueOfDerivativeLiability | Derivative Liability, Fair Value, Gross Liability | USD | 288,000 | 2021-03-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 | |
| us-gaap | DerivativeGainLossOnDerivativeNet | Derivative, Gain (Loss) on Derivative, Net | USD | 948,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | DerivativeLiabilities | Derivative Liability | USD | 10,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | DerivativeLiabilitiesNoncurrent | Derivative Liability, Noncurrent | USD | 29,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | DividendsCommonStock | Dividends, Common Stock | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | DividendsPaidinkind | Dividends, Paid-in-kind | USD | 0 | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-09 | 0001628280-23-038334 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -0.45 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -1.31 | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-04 | 0001628280-22-021070 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -0.45 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.296 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0.007 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.018 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | -0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxContingencies | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent | pure | -0.002 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.032 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent | Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent | pure | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 |
| us-gaap | EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | -20,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 3.58M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 18.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | EquityMethodInvestmentOwnershipPercentage | Equity Method Investment, Ownership Percentage | pure | 0.75 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | FairValueAdjustmentOfWarrants | Fair Value Adjustment of Warrants | USD | -4.60M | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-13 | 0001628280-24-047445 |
| us-gaap | FairValueAssumptionsExpectedDividendRate | Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) | pure | 0 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-10 | 0001564590-18-012719 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings | USD | -948,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances | USD | 41.25M | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-03 | 0001628280-22-028201 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net | USD | 374,000 | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-09 | 0001628280-23-038334 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | USD | 39,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FairValueOptionChangesInFairValueGainLoss1 | Fair Value, Option, Changes in Fair Value, Gain (Loss) | USD | 288,000 | 2019-01-01 | 2019-03-31 | 2020 | Q1 | 10-Q | 2020-05-07 | 0001628280-20-006998 |
| us-gaap | FinanceLeaseLiabilityPaymentsDue | Finance Lease, Liability, Payment, Due | USD | 33.66M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueNextTwelveMonths | Finance Lease, Liability, to be Paid, Year One | USD | 795,000 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 | |
| us-gaap | FiniteLivedIntangibleAssetsAccumulatedAmortization | Finite-Lived Intangible Assets, Accumulated Amortization | USD | 2.70M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive | Finite-Lived Intangible Asset, Expected Amortization, after Year Five | USD | 7.01M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths | Finite-Lived Intangible Asset, Expected Amortization, Year One | USD | 1.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year | USD | 277,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFive | Finite-Lived Intangible Asset, Expected Amortization, Year Five | USD | 1.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFour | Finite-Lived Intangible Asset, Expected Amortization, Year Four | USD | 1.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearThree | Finite-Lived Intangible Asset, Expected Amortization, Year Three | USD | 1.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo | Finite-Lived Intangible Asset, Expected Amortization, Year Two | USD | 1.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FiniteLivedIntangibleAssetsGross | Finite-Lived Intangible Assets, Gross | USD | 15.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | FiniteLivedIntangibleAssetsNet | Finite-Lived Intangible Assets, Net | USD | 12.82M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | GainLossOnDispositionOfAssets1 | Gain (Loss) on Disposition of Assets | USD | 105.00M | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-13 | 0001628280-24-047445 |
| us-gaap | GainLossOnDispositionOfIntangibleAssets | Gain (Loss) on Disposition of Intangible Assets | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | GainLossOnSaleOfOtherAssets | Gain (Loss) on Disposition of Other Assets | USD | 500,000 | 2023-07-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-09 | 0001628280-23-038334 |
| us-gaap | GainsLossesOnExtinguishmentOfDebt | Gain (Loss) on Extinguishment of Debt | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-21 | 0001628280-23-008745 |
| us-gaap | GainsLossesOnSalesOfAssets | Gain (Loss) on Disposition of Assets for Financial Service Operations | USD | 105.00M | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-13 | 0001628280-24-047445 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 24.48M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | Goodwill | Goodwill | USD | 17.35M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | GoodwillAcquiredDuringPeriod | Goodwill, Acquired During Period | USD | 0 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 |
| us-gaap | GoodwillGross | Goodwill, Gross | USD | 27.11M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | GoodwillImpairedAccumulatedImpairmentLoss | Goodwill, Impaired, Accumulated Impairment Loss | USD | 9.76M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | GoodwillImpairmentLoss | Goodwill, Impairment Loss | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | GoodwillPurchaseAccountingAdjustments | Goodwill, Purchase Accounting Adjustments | USD | 298,000 | 2019-04-01 | 2019-06-30 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -79.41M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -56.59M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | 251,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | USD | -61.98M | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-19 | 0001628280-21-005202 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 338,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 5,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | IncomeTaxPaidFederalAfterRefundReceived | IncomeTaxPaidFederalAfterRefundReceived | USD | 210,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxPaidStateAndLocalAfterRefundReceived | IncomeTaxPaidStateAndLocalAfterRefundReceived | USD | 90,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 23.44M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | USD | -24,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -16.62M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 548,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 1.45M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | 52,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | 10,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 2.56M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -815,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | 897,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | -9.84M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | IncreaseDecreaseInContractWithCustomerLiability | Increase (Decrease) in Contract with Customer, Liability | USD | 243,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | IncreaseDecreaseInInventories | Increase (Decrease) in Inventories | USD | 1.03M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 2.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | IntangibleAssetsNetExcludingGoodwill | Intangible Assets, Net (Excluding Goodwill) | USD | 4.90M | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-07 | 0001564590-19-029551 | |
| us-gaap | InterestExpense | Interest Expense | USD | 6.46M | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-13 | 0001628280-24-047445 |
| us-gaap | InterestExpenseNonoperating | InterestExpenseNonoperating | USD | 6.49M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 8.05M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | InventoryFinishedGoods | Inventory, Finished Goods, Gross | USD | 256,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | InventoryFinishedGoodsNetOfReserves | Inventory, Finished Goods, Net of Reserves | USD | 680,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | InventoryGross | Inventory, Gross | USD | 5.51M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | InventoryNet | Inventory, Net | USD | 2.82M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | InventoryRawMaterials | Inventory, Raw Materials, Gross | USD | 1.39M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | InventoryRawMaterialsNetOfReserves | Inventory, Raw Materials, Net of Reserves | USD | 1.53M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | InventoryWorkInProcess | Inventory, Work in Process, Gross | USD | 3.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | InventoryWorkInProcessNetOfReserves | Inventory, Work in Process, Net of Reserves | USD | 608,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 5.91M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | LeaseAndRentalExpense | Operating Leases, Rent Expense | USD | 1.30M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | LeaseCost | Lease, Cost | USD | 1.20M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 191,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 1.05M | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001628280-20-015792 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 1.05M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 47,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 45,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 51,000 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-08 | 0001628280-25-039327 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 306,000 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-08 | 0001628280-25-039327 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 765,000 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-06 | 0001501697-26-000040 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 2,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | Liabilities | Liabilities | USD | 92.93M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 231.82M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | LiabilitiesAssumed1 | Liabilities Assumed | USD | 403,000 | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 14.98M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | LiabilitiesFairValueDisclosure | Financial and Nonfinancial Liabilities, Fair Value Disclosure | USD | 987,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | LoansPayable | Loans Payable | USD | 7.89M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | LoansPayableCurrent | Loans Payable, Current | USD | 2.31M | 2017-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | LongTermDebt | Long-term Debt | USD | 75.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities | Long-term Debt and Lease Obligation, Including Current Maturities | USD | 54.32M | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-09 | 0001628280-23-038334 | |
| us-gaap | LongTermDebtCurrent | Long-term Debt, Current Maturities | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths | Long-Term Debt, Maturity, Year One | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive | Long-Term Debt, Maturity, Year Five | USD | 8.10M | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-07 | 0001628280-19-013715 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour | Long-Term Debt, Maturity, Year Four | USD | 11.31M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-19 | 0001628280-21-005202 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree | Long-Term Debt, Maturity, Year Three | USD | 76.08M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo | Long-Term Debt, Maturity, Year Two | USD | 76.70M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear | Long-Term Debt, Maturity, Remainder of Fiscal Year | USD | 0 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-05 | 0001501697-25-000043 | |
| us-gaap | LongTermDebtNoncurrent | Long-term Debt, Excluding Current Maturities | USD | 54.57M | 2023-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 | |
| us-gaap | LongTermLoansPayable | Loans Payable, Noncurrent | USD | 7.89M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | LossContingencyAccrualAtCarryingValue | Loss Contingency Accrual | USD | 1.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | MarketableSecurities | Marketable Securities | USD | 1.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | MarketableSecuritiesUnrealizedGainLoss | Marketable Securities, Unrealized Gain (Loss) | USD | 4,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | -35,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | NetCashProvidedByUsedInFinancingActivitiesContinuingOperations | Net Cash Provided by (Used in) Financing Activities, Continuing Operations | USD | -626,000 | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-10 | 0001564590-18-012719 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 29.25M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | NetCashProvidedByUsedInInvestingActivitiesContinuingOperations | Net Cash Provided by (Used in) Investing Activities, Continuing Operations | USD | -17,000 | 2017-01-01 | 2017-03-31 | 2018 | Q1 | 10-Q | 2018-05-10 | 0001564590-18-012719 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -60.57M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Net Cash Provided by (Used in) Operating Activities, Continuing Operations | USD | -12.18M | 2018-01-01 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-10 | 0001564590-18-012719 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -56.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -37.45M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 | Noncash or Part Noncash Acquisition, Fixed Assets Acquired | USD | 2,000 | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | NoncashOrPartNoncashAcquisitionPayablesAssumed1 | Noncash or Part Noncash Acquisition, Payables Assumed | USD | 60,000 | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 97,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | NumberOfReportingUnits | Number of Reporting Units | reporting_unit | 1 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 37.29M | 2024-01-01 | 2024-03-31 | 2024 | Q1 | 10-Q | 2024-05-07 | 0001628280-24-021120 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -56.69M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 1.20M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 189,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 189,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 861,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 264,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 2.96M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 884,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFiveYears | Operating Leases, Future Minimum Payments, Due in Five Years | USD | 263,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 492,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 835,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 823,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueThereafter | Operating Leases, Future Minimum Payments, Due Thereafter | USD | 263,000 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-09 | 0001564590-18-028766 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 810,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.115 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 1.47M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 338,000 | 2018-03-31 | 2018 | Q1 | 10-Q | 2018-05-10 | 0001564590-18-012719 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 3.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax | USD | -119,000 | 2019-01-01 | 2019-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 |
| us-gaap | OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | USD | 119,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax | USD | -119,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax | USD | -42,000 | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-07 | 0001564590-19-029551 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | -56.49M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 522,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | OtherNoncashIncomeExpense | Other Noncash Income (Expense) | USD | 69,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -264,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | OtherPrepaidExpenseCurrent | Other Prepaid Expense, Current | USD | 359,000 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | PaymentsForRepurchaseOfCommonStock | Payments for Repurchase of Common Stock | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | PaymentsForRepurchaseOfConvertiblePreferredStock | Payments for Repurchase of Convertible Preferred Stock | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-19 | 0001628280-21-005202 |
| us-gaap | PaymentsForRestructuring | Payments for Restructuring | USD | 1.69M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | PaymentsForSecuritiesPurchasedUnderAgreementsToResell | Payments for Securities Purchased under Agreements to Resell | USD | 3.00M | 2022-01-14 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | PaymentsOfDebtIssuanceCosts | Payments of Debt Issuance Costs | USD | 112,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | PaymentsOfFinancingCosts | Payments of Financing Costs | USD | 30,000 | 2016-01-01 | 2016-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 43,000 | 2018-01-01 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-09 | 0001564590-18-028766 |
| us-gaap | PaymentsRelatedToTaxWithholdingForShareBasedCompensation | Payment, Tax Withholding, Share-based Payment Arrangement | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | PaymentsToAcquireBusinessesNetOfCashAcquired | Payments to Acquire Businesses, Net of Cash Acquired | USD | 0 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001628280-20-015792 |
| us-gaap | PaymentsToAcquireIntangibleAssets | Payments to Acquire Intangible Assets | USD | 7.00M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | PaymentsToAcquireProductiveAssets | Payments to Acquire Productive Assets | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 326,000 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | PreferredStockValueOutstanding | Preferred Stock, Value, Outstanding | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 3.46M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | PrepaidInsurance | Prepaid Insurance | USD | 1.01M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | ProceedsFromConvertibleDebt | Proceeds from Convertible Debt | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-19 | 0001628280-21-005202 |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 46.00M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 1,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ProceedsFromIssuanceOfDebt | Proceeds from Issuance of Debt | USD | 694,000 | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | ProceedsFromIssuanceOfLongTermDebt | Proceeds from Issuance of Long-term Debt | USD | 0 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001628280-21-021795 |
| us-gaap | ProceedsFromIssuanceOfOtherLongTermDebt | Proceeds from Issuance of Other Long-term Debt | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 20.00M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock | Proceeds from Issuance of Redeemable Convertible Preferred Stock | USD | 40.05M | 2017-01-01 | 2017-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | ProceedsFromIssuanceOfSecuredDebt | Proceeds from Issuance of Secured Debt | USD | 20.00M | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-13 | 0001628280-24-047445 |
| us-gaap | ProceedsFromIssuanceOrSaleOfEquity | Proceeds from Issuance or Sale of Equity | USD | 58.10M | 2017-11-19 | 2017-11-20 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 34.25M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ProceedsFromSaleOfIntangibleAssets | Proceeds from Sale of Intangible Assets | USD | 105.00M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | ProceedsFromSalesOfAssetsInvestingActivities | Proceeds from Sales of Assets, Investing Activities | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 113,000 | 2019-01-01 | 2019-03-31 | 2019 | Q1 | 10-Q | 2019-05-15 | 0001193125-19-148119 |
| us-gaap | ProceedsFromStockPlans | Proceeds from Stock Plans | USD | 76,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -37.45M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 1.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 57,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | PurchaseObligation | Purchase Obligation | USD | 1.90M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | ReclassificationsOfTemporaryToPermanentEquity | Reclassifications of Temporary to Permanent Equity | USD | 38.75M | 2022-01-01 | 2022-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | RepaymentsOfLongTermDebt | Repayments of Long-term Debt | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | RepaymentsOfSecuredDebt | Repayments of Secured Debt | USD | 0 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-13 | 0001628280-24-047445 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 43.87M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | RestrictedCash | Restricted Cash | USD | 675,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 580,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | RestrictedCashNoncurrent | Restricted Cash, Noncurrent | USD | 95,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | RestrictedStockValueSharesIssuedNetOfTaxWithholdings | Restricted Stock, Value, Shares Issued Net of Tax Withholdings | USD | 0 | 2024-04-01 | 2024-06-30 | 2024 | Q3 | 10-Q | 2024-11-13 | 0001628280-24-047445 |
| us-gaap | RestructuringAndRelatedCostNumberOfPositionsEliminated | Restructuring and Related Cost, Number of Positions Eliminated | Employee | 28 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent | Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent | pure | 0.65 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent | Restructuring and Related Cost, Number of Positions Eliminated, Period Percent | pure | 0.65 | 2018-08-10 | 2019-03-01 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | RestructuringCharges | Restructuring Charges | USD | 235,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | RestructuringReserve | Restructuring Reserve | USD | 73,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -651.15M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 14.39M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | Revenues | Revenues | USD | 7.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | RoyaltyExpense | Royalty Expense | USD | 100,000 | 2025-04-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-08 | 0001628280-25-039327 |
| us-gaap | SaleOfStockPricePerShare | Sale of Stock, Price Per Share | USD/shares | 1.8 | 2021-03-23 | 2022 | Q1 | 10-Q | 2022-05-12 | 0001628280-22-014095 | |
| us-gaap | SeveranceCosts1 | Severance Costs | USD | 1.65M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 9.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | USD | 269 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | shares | 431,923 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-03 | 0001628280-22-028201 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares | 4.69M | 2023-01-01 | 2023-03-31 | 2022 | Q3 | 10-Q | 2023-05-04 | 0001628280-23-015763 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 4.5 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | shares | 5.84M | 2023-03-31 | 2022 | Q3 | 10-Q | 2023-05-04 | 0001628280-23-015763 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | USD/shares | 5.51 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | shares | 540,238 | 2023-01-01 | 2023-03-31 | 2022 | Q3 | 10-Q | 2023-05-04 | 0001628280-23-015763 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share | USD/shares | 4.69 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | USD/shares | 1.64 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-08 | 0001628280-25-039327 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 1.038 | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-08 | 0001628280-25-039327 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.042 | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-08 | 0001628280-25-039327 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number | shares | 10.41M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 6.30M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 4.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 2.48 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 1,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 1.23M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 5.06M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 11.77 | 2018-01-01 | 2018-09-30 | 2018 | Q3 | 10-Q | 2018-11-09 | 0001564590-18-028766 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares | 889,909 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value | USD/shares | 18.73 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | USD/shares | 12.35 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 15.55M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 15.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 2.5 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | shares | 1.05M | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | USD/shares | 2.53 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 13.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares | 14.20M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | USD | 4.50M | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 1.5 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 7.04 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 4 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | SharesOutstanding | Shares, Outstanding | shares | 16.29M | 2020-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001628280-21-021795 | |
| us-gaap | ShortTermLeaseCost | Short-term Lease, Cost | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 138.88M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.033 | 2025-04-28 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities | Stock Issued During Period, Shares, Conversion of Convertible Securities | shares | 7.18M | 2017-11-19 | 2017-11-20 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans | Stock Issued During Period, Shares, Employee Stock Purchase Plans | shares | 257,963 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | StockIssuedDuringPeriodSharesIssuedForServices | Stock Issued During Period, Shares, Issued for Services | shares | 1,000 | 2021-01-01 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-06 | 0001628280-21-009166 |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 900,000 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-12 | 0001628280-22-014095 |
| us-gaap | StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures | Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | shares | 132,537 | 2020-01-01 | 2020-12-31 | 2022 | FY | 10-K | 2023-03-21 | 0001628280-23-008745 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 2,031 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | StockIssuedDuringPeriodValueAcquisitions | Stock Issued During Period, Value, Acquisitions | USD | 45.54M | 2019-01-01 | 2019-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 64.67M | 2019-01-01 | 2019-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan | Stock Issued During Period, Value, Employee Stock Ownership Plan | USD | 76,000 | 2026-04-01 | 2026-06-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 297,000 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 86.68M | 2025-07-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardGross | Stock Issued During Period, Value, Restricted Stock Award, Gross | USD | 2,000 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-26 | 0001628280-25-014805 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures | USD | 0 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 40,000 | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | StockRepurchasedAndRetiredDuringPeriodShares | Stock Repurchased and Retired During Period, Shares | shares | 229,885 | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | StockRepurchasedAndRetiredDuringPeriodValue | Stock Repurchased and Retired During Period, Value | USD | 0 | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | SubleaseIncome | Sublease Income | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | TemporaryEquityAccretionToRedemptionValueAdjustment | Temporary Equity, Accretion to Redemption Value, Adjustment | USD | 0 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001628280-20-015792 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 1.88M | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-03 | 0001628280-21-015330 | |
| us-gaap | TemporaryEquityDividendsAdjustment | Temporary Equity, Dividends, Adjustment | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 |
| us-gaap | TemporaryEquityLiquidationPreference | Temporary Equity, Liquidation Preference | USD | 84.07M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 49.41M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | TemporaryEquitySharesIssued | Temporary Equity, Shares Issued | shares | 40.08M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | TemporaryEquitySharesOutstanding | Temporary Equity, Shares Outstanding | shares | 40.08M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001628280-20-003484 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 200,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 | |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition | Unrecognized Tax Benefits, Increase Resulting from Acquisition | USD | 100,000 | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-03-21 | 0001628280-24-012578 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 94,000 | 2018-01-01 | 2018-12-31 | 2018 | FY | 10-K | 2019-03-11 | 0001564590-19-007097 |
| us-gaap | UnrecognizedTaxBenefitsPeriodIncreaseDecrease | Unrecognized Tax Benefits, Period Increase (Decrease) | USD | -100,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-17 | 0001628280-22-006547 |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 29.28M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-17 | 0001501697-26-000018 |
| us-gaap | WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount | Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount | USD | 2.55M | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-03 | 0001628280-22-028201 |
| us-gaap | WeightedAverageDiscountRatePercent | Weighted Average Discount Rate, Percent (Deprecated 2019-01-31) | pure | 0.195 | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-07 | 0001564590-19-029551 |
| us-gaap | WeightedAverageNumberDilutedSharesOutstandingAdjustment | Weighted Average Number Diluted Shares Outstanding Adjustment | shares | 0 | 2026-01-01 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-06 | 0001501697-26-000040 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 126.33M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 34.59M | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 10-Q | 2022-08-04 | 0001628280-22-021070 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 126.33M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-04 | 0001501697-26-000089 |